Synthesis, characterization and cytotoxicity of copper (II) complex containing a 2H-benzo[e][1,3]oxazin derivative.

Autor: de Oliveira JAF; Departamento de Química, Universidade Federal de Santa Catarina, Florianópolis, SC 88040-900, Brazil., Terra GG; Departamento de Química, Universidade Federal de Santa Catarina, Florianópolis, SC 88040-900, Brazil., Costa TG; Departamento de Química, Universidade Federal de Santa Catarina, Florianópolis, SC 88040-900, Brazil., Szpoganicz B; Departamento de Química, Universidade Federal de Santa Catarina, Florianópolis, SC 88040-900, Brazil., Silva-Caldeira PP; Departamento de Química, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil., de Souza ÍP; Departamento de Química, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil., Pereira-Maia EC; Departamento de Química, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil., Bortoluzzi AJ; Departamento de Química, Universidade Federal de Santa Catarina, Florianópolis, SC 88040-900, Brazil. Electronic address: adailton.bortoluzzi@ufsc.br.
Jazyk: angličtina
Zdroj: Journal of inorganic biochemistry [J Inorg Biochem] 2023 Feb; Vol. 239, pp. 112087. Date of Electronic Publication: 2022 Dec 01.
DOI: 10.1016/j.jinorgbio.2022.112087
Abstrakt: A new cis-dihalo copper(II) complex, [Cu II (HL bz )(Cl) 2 ].CH 3 CN (1), where HL bz  = (S)-2-(((2-(2-(pyridin-2-yl)-2H-benzo[e][1,3]oxazin-3(4H)-yl)ethyl)amino)methyl)phenol), was isolated by reacting copper(II) chloride dihydrate and the H 2 L ligand (H 2 L = 2,2'-((2-(pyridin-2-yl)imidazolidine-1,3-diyl)bis(methylene))diphenol) in a MeOH/CH 3 CN (1:3 v/v) mixture. The complex formation occurred via the ligand modification during complexation, producing a unique structure containing 2H-benzo[e][1,3]oxazin, as observed from the single crystal X-ray structure determination. The complex was characterized by elemental analysis, potentiometric titration, spectroscopic techniques (UV-Vis, FT-IR) and conductance measurements. Complex 1 inhibits the growth of myelogenous leukemia cells with an IC 50 of 17.3 μmol L -1 .
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: